Corporate Information, English, IR, News, Other Corporate Information

CEO purchases shares in Acarix

02 Sep

Acarix, a leader in advanced acoustic-based cardiac diagnostics, announces that Aamir Mahmood, President and CEO of Acarix, purchased 2,261,753 shares in the company between August 29 and August 30 at an average price of SEK 0.2866 per share. His total ownership now amounts to 5,404,567 shares.

“I have great confidence in the company, and this is a way for me to deepen my commitment also as a shareholder” said Aamir Mahmood, President and CEO of Acarix.

For more information contact:
Jennifer Monies, phone +1 (405) 550-8144, jmonies@saxum.com

About Acarix

Acarix is a Swedish medical device company that innovates solutions for rapid rule out of coronary artery disease (CAD) at point of care. The CE-approved and FDA DeNovo-cleared Acarix CADScor System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive, and costly diagnostic procedures. The CADScor System has been used on more than 29,000 patients. Acarix recommends CADScor System as a first-line diagnostic aid that uses highly sensitive acoustics and advanced computational processing to analyze coronary blood flow to rule out significant coronary artery disease (CAD), with at least 96% certainty at point of care. Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX) and cross-traded on the OTCQB market in the US (ticker: ACIXF). Carnegie Investment Bank is the Certified Advisor of Acarix. For more information, please visit www.acarix.com

Attachments
CEO purchases shares in Acarix

CEO purchases shares in Acarix
Newer Nationally Recognized Cardiology Practice Places Multiunit Order of the Acarix CADScor System
Back to list
Older FILTER-SCAD Study Results Demonstrate Need for Point of Care Rule-Out Options for Coronary Artery Disease in Low-Risk Patients